Pharma Stocks Outlook
Fundamental outlook strong on India-EU deal
This story was originally published at 23:02 IST on 30 January 2026
Register to read our real-time news.Informist, Friday, Jan. 30, 2026
MUMBAI – The Free Trade Agreement with the European Union is expected to be a game-changer for India's pharmaceutical sector, with experts predicting a significant boost for the industry if and when the recently signed pact gets ratified. "The agreement will strengthen India's position as a global healthcare manufacturing hub and expand employment opportunities," media reports quoted Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, as saying.
With tariffs on pharmaceutical products set to be eliminated, Indian companies are likely to see increased exports and improved access to the EU market. Yet, in the near term, technical analysts have a cautious outlook, with the Nifty Pharma index expected to perform poorly in the coming week.
The trade deal is expected to reduce drug prices by up to 20%, making medicines more affordable for Indian patients. The removal of EU tariffs of up to 11% on pharmaceuticals will enhance trade and support greater access to innovative medicines. Indian companies like Mankind Pharma and Iberia Pharmaceuticals are likely to benefit from the agreement.
The Nifty Pharma index has seen a decline in the past quarter, and investors may do well to be cautious, analysts said. The index is expected to fall next week and is likely to find support around 20500 points and resistance is seen around 21200 points. This is lower than the index's closing level of 21715.10 points Friday. This week, the index fell marginally. Gland Pharma was the top performer this week, ending up nearly 10% at INR 1,846.60. Laurus Labs was the worst performer this week, falling over 5% to close at INR 965 on the National Stock Exchange.
The December quarter results of Apollo Hospitals Enterprises is eagerly awaited, with investors looking for insights into the company's performance and future prospects. The stock has seen a steady performance, ending 2% higher at INR 6,960.50 on Friday.
TOP HEADLINES
* Max Healthcare's Nigeria-based subsidiary initiates voluntary liquidation
* Earnings Outlook: Sun Pharma Q3 consol PAT to fall on US drag; sales seen up
* Analyst Concall: Dabur to start raising prices in Q4, continue through FY27
* Gland Pharma COO Satnam Singh Loomba to retire on Mar 31
* Earnings Review: Dabur India Q3 PAT up on easing of GST-related disruptions
* ER Squibb moves SC to bar Zydus Life from selling biosimilar of Nivolumab
* Piramal Pharma posts consol net loss Q3 vs PAT yr ago, revenue down 3% YoY
* Biocon's Andhra unit gets voluntary action indicated status from US FDA
* Gland Pharma Oct-Dec consol PAT rises almost 28% YoY to INR 2.61 billion
* S&P Global ups Biocon arm long-term rtg to 'BB+', revises outlook to stable
* Caplin Point arm gets US FDA OK for methylprednisolone acetate injectable
* Alembic Pharma gets US FDA final nod for difluprednate ophthalmic emulsion
* Earnings Outlook: Dabur Q3 PAT, sales growth seen subdued on GST disruption
* Torrent Pharmaceuticals raises stake in JB Chemicals to 48.78%
* IPO Alert: Medicap Healthcare gets SEBI approval for INR-2.4-bln fresh issue
* OneSource Specialty consol net loss widens YoY to INR 887 mln in Oct-Dec
* Analyst Concall: Cipla seen revising FY27 US sales guidance of $1 bln
* CIpla cuts FY26 EBITDA margin view; Lanreotide supply woes to continue in Q4
* Zydus Life's Ankleshwar unit gets 3 US FDA observations
* Granules India Oct-Dec consol PAT rises nearly 28% YoY to INR 1.5 billion
* Earnings Review: Weak North America sales drag down Cipla's Q3 PAT 57% YoY
* Laurus Labs Oct-Dec consol PAT rises nearly 3-fold on year to INR 2.52 bln
Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 27565.00 | (-)0.80 | 28895.00 | 25765.00 |
| Alkem Laboratories | 5677.50 | (-)1.30 | 5799.20 | 5579.20 |
| Aurobindo Pharma | 1207.70 | 6.60 | 1245.20 | 1155.20 |
| Biocon | 366.80 | 0.20 | 372.90 | 356.90 |
| Cipla | 1324.00 | 0.70 | 1338.30 | 1307.30 |
| Divi's Laboratories | 6051.00 | 0.70 | 6140.70 | 5929.70 |
| Dr Reddy's Laboratories | 1218.10 | (-)1.40 | 1239.10 | 1189.50 |
| Gland Pharma | 1846.60 | 9.80 | 1927.30 | 1741.70 |
| GlaxoSmithKline Pharmaceuticals | 2401.60 | 3.80 | 2481.70 | 2266.30 |
| Glenmark Pharmaceuticals | 2015.90 | 2.50 | 2087.60 | 1893.00 |
| Granules India | 570.60 | 1.00 | 583.10 | 558.60 |
| Ipca Laboratories | 1470.80 | 0.60 | 1528.90 | 1414.90 |
| Laurus Labs | 965.00 | (-)5.10 | 998.20 | 935.20 |
| Lupin | 2152.80 | 0.70 | 2194.70 | 2099.30 |
| Natco Pharma | 835.90 | 0.50 | 863.00 | 792.50 |
| Pfizer | 4563.60 | (-)0.60 | 4653.90 | 4495.90 |
| Sanofi India | 4017.70 | (-)1.20 | 4098.50 | 3960.70 |
| Sun Pharmaceutical Industries | 1595.30 | (-)2.20 | 1617.00 | 1574.20 |
| Torrent Pharmaceuticals | 3960.80 | 0.70 | 4202.10 | 3574.30 |
| Zydus Lifesciences | 885.30 | 0.40 | 901.70 | 874.30 |
| Index | Levels | |||
| Nifty Pharma | 21715.10 | (-)0.00 | 21999.30 | 21254.20 |
| Nifty 50 | 25320.65 | 1.10 | 25458.70 | 25144.60 |
| S&P BSE Sensex | 82269.78 | 0.90 | 82703.70 | 81724.10 |
End
Reported by P. Madhu Kumar
Edited by Ashish Shirke
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
